|
Physiomics PLC shares jumped on Wednesday after it signed an agreement to work with Cancer Research UK.
Shares in the oncology consultancy based in Oxford, England were up 24% to 2.60 pence each in London on Wednesday morning.
Physiomics said it will use its PKPD modelling capabilities to support the Cancer Research-sponsored early phase clinical development of ALETA-001, a CAR-T cell engager candidate for the treatment of blood cancers developed by Aleta Biotherapeutics.
The PKPD modelling project is expected to be completed by the end of 2022.
Chief Executive Jim Millen said: ‘We are delighted to be working with Cancer Research UK, the world's leading cancer charity. Although we have previously worked with clients whose early clinical trials are sponsored by Cancer Research UK's Centre for Drug Development, this project marks the first occasion on which Physiomics has worked directly with Cancer Research UK.’
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
